KF
ALNY icon

Krilogy Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Krilogy Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316K Sell
1,050
-123
-10% -$37.1K 0.01% 803
2026
Q1 		$376K Sell
1,173
-414
-26% -$141K 0.01% 669
2025
Q4 		$573K Sell
1,587
-2,235
-58% -$989K 0.02% 516
2025
Q3 		$1.66M Buy
+3,822
New +$1.56M 0.06% 221

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Krilogy Financial's ALNY Position: Q2 2026 in Review

Krilogy Financial reduced its Alnylam Pharmaceuticals (ALNY) stake by 10% in Q2 2026, selling an estimated $37.1K and leaving 1,050 shares worth $316K. The position accounts for 0.01% of the portfolio, ranked #803.

Krilogy Financial first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.66M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Krilogy Financial held 1,050 shares of Alnylam Pharmaceuticals worth $316K as of Q2 2026.
  • Krilogy Financial sold 123 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $37.1K.
  • Alnylam Pharmaceuticals made up 0.01% of Krilogy Financial's portfolio in Q2 2026, its #803 holding.
  • Krilogy Financial first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Krilogy Financial's Alnylam Pharmaceuticals position peaked at $1.66M in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.